Literature DB >> 19457102

Impaired dopamine release and synaptic plasticity in the striatum of parkin-/- mice.

Tohru Kitada1, Antonio Pisani, Maha Karouani, Marian Haburcak, Giuseppina Martella, Anne Tscherter, Paola Platania, Bei Wu, Emmanuel N Pothos, Jie Shen.   

Abstract

Parkin is the most common causative gene of juvenile and early-onset familial Parkinson's diseases and is thought to function as an E3 ubiquitin ligase in the ubiquitin-proteasome system. However, it remains unclear how loss of Parkin protein causes dopaminergic dysfunction and nigral neurodegeneration. To investigate the pathogenic mechanism underlying these mutations, we used parkin-/- mice to study its physiological function in the nigrostriatal circuit. Amperometric recordings showed decreases in evoked dopamine release in acute striatal slices of parkin-/- mice and reductions in the total catecholamine release and quantal size in dissociated chromaffin cells derived from parkin-/- mice. Intracellular recordings of striatal medium spiny neurons revealed impairments of long-term depression and long-term potentiation in parkin-/- mice, whereas long-term potentiation was normal in the Schaeffer collateral pathway of the hippocampus. Levels of dopamine receptors and dopamine transporters were normal in the parkin-/- striatum. These results indicate that Parkin is involved in the regulation of evoked dopamine release and striatal synaptic plasticity in the nigrostriatal pathway, and suggest that impairment in evoked dopamine release may represent a common pathophysiological change in recessive parkinsonism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19457102     DOI: 10.1111/j.1471-4159.2009.06152.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  59 in total

1.  Altered hippocampal synaptic physiology in aged parkin-deficient mice.

Authors:  Jesse E Hanson; Adrienne L Orr; Daniel V Madison
Journal:  Neuromolecular Med       Date:  2010-03-16       Impact factor: 3.843

Review 2.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

3.  RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits.

Authors:  Talia N Lerner; Anatol C Kreitzer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

4.  Impaired neurotransmitter release in Alzheimer's and Parkinson's diseases.

Authors:  Jie Shen
Journal:  Neurodegener Dis       Date:  2010-02-18       Impact factor: 2.977

Review 5.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

Review 6.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

Review 7.  Autophagy in Parkinson's Disease.

Authors:  Xu Hou; Jens O Watzlawik; Fabienne C Fiesel; Wolfdieter Springer
Journal:  J Mol Biol       Date:  2020-02-13       Impact factor: 5.469

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  The PINK1/Parkin pathway: a mitochondrial quality control system?

Authors:  Alexander J Whitworth; Leo J Pallanck
Journal:  J Bioenerg Biomembr       Date:  2009-12       Impact factor: 2.945

10.  Inactivation of presenilins causes pre-synaptic impairment prior to post-synaptic dysfunction.

Authors:  Dawei Zhang; Chen Zhang; Angela Ho; Alfredo Kirkwood; Thomas C Südhof; Jie Shen
Journal:  J Neurochem       Date:  2010-10-26       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.